PAK6 and cancer: Somatic acquired PAK6 point mutations have been discovered in cancer, and interestingly, a recurrent PAK6 mutation that has been observed in two independent melanomas [17], [18] occurs by substituting residue P52 within the pseudosubstrate autoinhibitory region with a leucine.